ATE553206T1 - Expression von genen mit überlappenden offenen leserastern in insektenzellen, verfahren und zusammensetzungen dafür - Google Patents
Expression von genen mit überlappenden offenen leserastern in insektenzellen, verfahren und zusammensetzungen dafürInfo
- Publication number
- ATE553206T1 ATE553206T1 AT07814439T AT07814439T ATE553206T1 AT E553206 T1 ATE553206 T1 AT E553206T1 AT 07814439 T AT07814439 T AT 07814439T AT 07814439 T AT07814439 T AT 07814439T AT E553206 T1 ATE553206 T1 AT E553206T1
- Authority
- AT
- Austria
- Prior art keywords
- insect cells
- methods
- open reading
- gene
- genes
- Prior art date
Links
- 241000238631 Hexapoda Species 0.000 title abstract 6
- 108090000623 proteins and genes Proteins 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title 1
- 108700026244 Open Reading Frames Proteins 0.000 abstract 2
- 241000702421 Dependoparvovirus Species 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/00041—Use of virus, viral particle or viral elements as a vector
- C12N2750/00043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/00051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14151—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14151—Methods of production or purification of viral material
- C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/103—Plasmid DNA for invertebrates
- C12N2800/105—Plasmid DNA for invertebrates for insects
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/50—Vectors for producing vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83976106P | 2006-08-24 | 2006-08-24 | |
| PCT/US2007/076799 WO2008024998A2 (en) | 2006-08-24 | 2007-08-24 | Expression in insect cells of genes with overlapping open reading frames, methods and compositions therefor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE553206T1 true ATE553206T1 (de) | 2012-04-15 |
Family
ID=39107735
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT07814439T ATE553206T1 (de) | 2006-08-24 | 2007-08-24 | Expression von genen mit überlappenden offenen leserastern in insektenzellen, verfahren und zusammensetzungen dafür |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US8945918B2 (de) |
| EP (1) | EP2061891B1 (de) |
| CN (1) | CN101522903B (de) |
| AT (1) | ATE553206T1 (de) |
| DK (1) | DK2061891T3 (de) |
| ES (1) | ES2385679T3 (de) |
| WO (1) | WO2008024998A2 (de) |
Families Citing this family (91)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011512156A (ja) * | 2008-02-19 | 2011-04-21 | アムステルダム モレキュラー セラピューティクス ビー．ブイ． | 昆虫細胞におけるパルボウイルスｒｅｐ及びｃａｐタンパク質の発現の最適化 |
| US20110319478A1 (en) | 2010-06-04 | 2011-12-29 | Medtronic, Inc. | Compositions to Treat Cardiac Pacing Conditions |
| EP2788489B1 (de) | 2011-12-08 | 2017-03-15 | Virovek, Inc. | Vektoren mit toxischen genen, verfahren und verwendungen dafür |
| CN104363961B (zh) | 2012-02-21 | 2017-10-03 | 斯坦福大学托管董事会 | 用于治疗盆底神经源性病症的组合物和方法 |
| TWI698240B (zh) | 2012-05-15 | 2020-07-11 | 澳大利亞商艾佛蘭屈澳洲私營有限公司 | 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd) |
| CN105142529A (zh) | 2012-11-21 | 2015-12-09 | 电路治疗公司 | 用于光遗传疗法的系统和方法 |
| JP6594854B2 (ja) | 2013-03-15 | 2019-10-23 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 行動状態の光遺伝学的制御方法 |
| JP6549559B2 (ja) | 2013-04-29 | 2019-07-24 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 標的細胞における活動電位の光遺伝学的調節のための装置、システム及び方法 |
| JP6621747B2 (ja) | 2013-08-14 | 2019-12-18 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 疼痛を制御するための組成物及び方法 |
| DK3089760T3 (da) | 2013-12-31 | 2020-03-16 | Proteonic Biotechnology Ip B V | Konstrukt og sekvens til forbedret genekspression |
| GB201403684D0 (en) | 2014-03-03 | 2014-04-16 | King S College London | Vector |
| EP3800191B1 (de) | 2014-03-17 | 2025-08-20 | Adverum Biotechnologies, Inc. | Zusammensetzungen und verfahren zur verbesserten genexpression in zapfenzellen |
| BR112016019940A2 (pt) | 2014-03-21 | 2017-10-24 | Univ Leland Stanford Junior | edição de genoma sem nucleases |
| CN106459138A (zh) | 2014-03-28 | 2017-02-22 | 斯坦福大学托管董事会 | 工程化的光激活阴离子通道蛋白及其使用方法 |
| EP3151866B1 (de) | 2014-06-09 | 2023-03-08 | Voyager Therapeutics, Inc. | Chimäre kapside |
| RU2716991C2 (ru) | 2014-11-05 | 2020-03-17 | Вояджер Терапьютикс, Инк. | Полинуклеотиды aadc для лечения болезни паркинсона |
| KR20230145206A (ko) | 2014-11-14 | 2023-10-17 | 보이저 테라퓨틱스, 인크. | 조절성 폴리뉴클레오티드 |
| WO2016077687A1 (en) | 2014-11-14 | 2016-05-19 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (als) |
| US11697825B2 (en) | 2014-12-12 | 2023-07-11 | Voyager Therapeutics, Inc. | Compositions and methods for the production of scAAV |
| US11021519B2 (en) | 2015-03-02 | 2021-06-01 | Adverum Biotechnologies, Inc. | Compositions and methods for intravitreal delivery of polynucleotides to retinal cones |
| JP6836999B2 (ja) | 2015-03-24 | 2021-03-03 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ | アデノ随伴ウイルス変異体及びその使用方法 |
| JP7097070B2 (ja) | 2015-10-01 | 2022-07-07 | ゴレイニ インコーポレイテッド | クロライドチャネルの標的発現及びその使用方法 |
| US10406244B2 (en) | 2015-12-02 | 2019-09-10 | The Board Of Trustees Of The Leland Stanford Junior University | AAV vectors with expanded packaging capacity |
| EP3384034B1 (de) | 2015-12-02 | 2020-07-08 | The Board of Trustees of the Leland Stanford Junior University | Neue rekombinante kapside des adeno-associated virus mit erhöhtem tropismus für menschliche skelett- muskulatur |
| GB2545763A (en) | 2015-12-23 | 2017-06-28 | Adverum Biotechnologies Inc | Mutant viral capsid libraries and related systems and methods |
| JP6947739B2 (ja) | 2016-02-16 | 2021-10-13 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 既存のヒト中和抗体に対して耐性である新規組換えアデノ随伴ウイルスカプシド |
| JP7496667B2 (ja) | 2016-04-21 | 2024-06-07 | ビロベク，インコーポレイテッド | 昆虫細胞中でのａａｖ生成、方法およびその組成物 |
| US11299751B2 (en) | 2016-04-29 | 2022-04-12 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| EP3448874A4 (de) | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | Zusammensetzungen zur behandlung einer erkrankung |
| KR102427379B1 (ko) | 2016-05-18 | 2022-08-02 | 보이저 테라퓨틱스, 인크. | 헌팅톤 질환을 치료하기 위한 조성물 및 방법 |
| KR20240056729A (ko) | 2016-05-18 | 2024-04-30 | 보이저 테라퓨틱스, 인크. | 조절성 폴리뉴클레오티드 |
| WO2018044933A1 (en) | 2016-08-30 | 2018-03-08 | The Regents Of The University Of California | Methods for biomedical targeting and delivery and devices and systems for practicing the same |
| WO2018195555A1 (en) | 2017-04-21 | 2018-10-25 | The Board Of Trustees Of The Leland Stanford Junior University | Crispr/cas 9-mediated integration of polynucleotides by sequential homologous recombination of aav donor vectors |
| JP2020518259A (ja) | 2017-05-05 | 2020-06-25 | ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | ハンチントン病治療組成物および方法 |
| JP2020518258A (ja) | 2017-05-05 | 2020-06-25 | ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 筋萎縮性側索硬化症（ａｌｓ）治療組成物および方法 |
| JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
| JP7764129B2 (ja) | 2017-07-10 | 2025-11-05 | ユニキュアー アイピー ビー．ブイ． | ヒトにおけるａａｖ遺伝子療法のための手段及び方法 |
| CA3070087A1 (en) | 2017-07-17 | 2019-01-24 | Voyager Therapeutics, Inc. | Trajectory array guide system |
| NZ762100A (en) | 2017-08-09 | 2025-12-19 | Bioverativ Therapeutics Inc | Nucleic acid molecules and uses thereof |
| AU2018338728B2 (en) | 2017-09-29 | 2025-01-02 | Centre National De La Recherche Scientifique (Cnrs) | Rescue of central and peripheral neurological phenotype of Friedreich's Ataxia by intravenous delivery |
| US20200231986A1 (en) | 2017-09-29 | 2020-07-23 | Massachusetts Eye And Ear Infirmary | Production of adeno-associated viruses in insect cells |
| TW202413649A (zh) | 2017-10-16 | 2024-04-01 | 美商航海家醫療公司 | 肌萎縮性脊髓側索硬化症(als)之治療 |
| SI3740222T1 (sl) | 2018-01-17 | 2023-11-30 | Meiragtx Uk Ii Limited | Modificiran kapsidni protein raav za gensko terapijo |
| EP3774853A1 (de) | 2018-03-30 | 2021-02-17 | The Board of Trustees of the Leland Stanford Junior University | Neuartige kapside des rekombinanten adeno-assoziierten virus mit erhöhtem menschlichem pankreatischem tropismus |
| KR20210019996A (ko) | 2018-05-15 | 2021-02-23 | 보이저 테라퓨틱스, 인크. | 파킨슨병의 치료를 위한 조성물 및 방법 |
| WO2019237375A1 (zh) * | 2018-06-16 | 2019-12-19 | 深圳市博奥康生物科技有限公司 | 一种将hdmx基因定点整合至mcf-7细胞的方法及其应用 |
| EP3833766A1 (de) | 2018-08-09 | 2021-06-16 | Bioverativ Therapeutics Inc. | Nukleinsäuremoleküle und verwendungen davon zur nichtviralen gentherapie |
| EP3856762A1 (de) | 2018-09-28 | 2021-08-04 | Voyager Therapeutics, Inc. | Frataxin-expressionskonstrukte mit gentechnisch veränderten promotoren und verfahren zu deren verwendung |
| CN113166208B (zh) | 2018-10-02 | 2024-11-22 | 沃雅戈治疗公司 | 重新定向aav衣壳的嗜性 |
| WO2020072844A1 (en) * | 2018-10-05 | 2020-04-09 | Voyager Therapeutics, Inc. | Engineered nucleic acid constructs encoding aav production proteins |
| WO2020160508A1 (en) | 2019-01-31 | 2020-08-06 | Oregon Health & Science University | Methods for using transcription-dependent directed evolution of aav capsids |
| CN113728108A (zh) | 2019-02-15 | 2021-11-30 | 桑格摩生物治疗股份有限公司 | 用于生产重组aav的组合物和方法 |
| EP3947700A4 (de) | 2019-04-01 | 2023-01-04 | Tenaya Therapeutics, Inc. | Adeno-assoziiertes virus mit manipuliertem kapsid |
| CA3136004A1 (en) | 2019-04-10 | 2020-10-15 | Prevail Therapeutics, Inc. | Gene therapies for lysosomal disorders |
| JP7664848B2 (ja) | 2019-04-10 | 2025-04-18 | プリベイル セラピューティクス，インコーポレーテッド | リソソーム障害のための遺伝子療法 |
| MX2022000551A (es) | 2019-07-15 | 2022-05-18 | Meiragtx Uk Ii Ltd | Proteínas de la cápside de aav modificadas para el tratamiento de una enfermedad artrítica. |
| US10557149B1 (en) | 2019-07-15 | 2020-02-11 | Vigene Biosciences, Inc. | Recombinantly-modified adeno-associated virus helper vectors and their use to improve the packaging efficiency of recombinantly-modified adeno-associated virus |
| US10801042B1 (en) | 2019-07-15 | 2020-10-13 | Vigene Biosciences, Inc. | Use of ion concentrations to increase the packaging efficiency of recombinant adeno-associated virus |
| US10653731B1 (en) | 2019-07-15 | 2020-05-19 | Vigene Biosciences Inc. | Recombinantly-modified adeno-associated virus (rAAV) having improved packaging efficiency |
| JP7598920B2 (ja) | 2019-07-23 | 2024-12-12 | ヤンセン バイオテツク，インコーポレーテツド | 生物製造のための合成遺伝子要素 |
| EP4069856A1 (de) | 2019-12-04 | 2022-10-12 | Sangamo Therapeutics, Inc. | Neuartige zusammensetzungen und verfahren zur herstellung von rekombinantem aav |
| CN111004803B (zh) * | 2019-12-31 | 2023-05-16 | 中山大学 | 褐飞虱NlStit基因作为靶点在制备防治褐飞虱药物中的应用 |
| EP4127135A1 (de) | 2020-04-02 | 2023-02-08 | uniQure biopharma B.V. | Duale bifunktionelle vektoren zur aav-herstellung |
| EP4127146A1 (de) | 2020-04-02 | 2023-02-08 | uniQure biopharma B.V. | Neue zelllinie |
| TWI900553B (zh) | 2020-05-13 | 2025-10-11 | 美商航海家醫療公司 | Aav蛋白殼之趨性重定向 |
| JP2023537903A (ja) | 2020-08-10 | 2023-09-06 | プリベイル セラピューティクス，インコーポレーテッド | リソソーム障害に対する遺伝子療法 |
| AU2021325891A1 (en) | 2020-08-10 | 2023-04-06 | Prevail Therapeutics, Inc. | Gene therapies for neurodegenerative disorders |
| BR112023006305A2 (pt) | 2020-10-09 | 2023-05-09 | Tenaya Therapeutics Inc | Métodos e composições de terapia gênica com placofilina-2 |
| CN112852882A (zh) * | 2021-02-04 | 2021-05-28 | 中吉智药(南京)生物技术有限公司 | 一种杆状病毒感染昆虫细胞生产aav基因药物的系统及方法 |
| US20240124850A1 (en) | 2021-03-03 | 2024-04-18 | Shape Therapeutics Inc. | Auxotrophic Cells for Virus Production and Compositions and Methods of Making |
| WO2022207899A1 (en) | 2021-04-02 | 2022-10-06 | Uniqure Biopharma B.V. | Methods for producing single insect cell clones |
| AU2022286647A1 (en) | 2021-06-02 | 2023-11-30 | Uniqure Biopharma B.V. | Insect cell production of parvoviral vectors with modified capsid proteins |
| JP2024521537A (ja) * | 2021-06-23 | 2024-05-31 | フロンテーラ セラピューティクス，インク． | 血友病ｂを処置するための組成物および方法 |
| EP4392434A1 (de) | 2021-08-26 | 2024-07-03 | uniQure biopharma B.V. | Durch insektenzellen produzierte hochwirksame aav-vektoren mit zns-tropismus |
| CN113897396B (zh) * | 2021-09-18 | 2022-08-30 | 劲帆生物医药科技（武汉）有限公司 | 一种用于在昆虫细胞中表达包含重叠开放阅读框的基因的表达盒及其应用 |
| EP4426716A1 (de) | 2021-11-02 | 2024-09-11 | Voyager Therapeutics, Inc. | Aav-kapsidvarianten und verwendungen davon |
| CN114150021B (zh) | 2021-11-26 | 2022-10-28 | 劲帆生物医药科技（武汉）有限公司 | 一种包含重叠开放阅读框的基因的表达盒及其在昆虫细胞中的应用 |
| JP2024545923A (ja) | 2021-12-30 | 2024-12-13 | リーゲル セラピューティクス，インコーポレイティッド | ナトリウム電位依存性チャネルアルファサブユニット１の発現を調節するための組成物、及びその使用 |
| WO2023201207A1 (en) | 2022-04-11 | 2023-10-19 | Tenaya Therapeutics, Inc. | Adeno-associated virus with engineered capsid |
| CN119403933A (zh) | 2022-06-21 | 2025-02-07 | 里格尔医疗股份有限公司 | 遗传调控元件及其用途 |
| WO2024047587A1 (en) | 2022-08-31 | 2024-03-07 | Regel Therapeutics, Inc. | Cas-phi compositions and methods of use |
| EP4598940A1 (de) | 2022-10-04 | 2025-08-13 | Eli Lilly and Company | Gentherapie für trem2-assoziierte erkrankungen und störungen |
| AU2023375569A1 (en) | 2022-11-11 | 2025-05-29 | Eli Lilly And Company | Synthetic nucleic acids including astrocyte-directed promoter constructs and methods of using the same |
| AU2024258816A1 (en) | 2023-04-18 | 2025-10-23 | Uniqure Biopharma B.V. | Generation of adeno-associated virus capsid libraries for insect cells |
| WO2024249172A1 (en) | 2023-05-26 | 2024-12-05 | Regel Therapeutics, Inc. | Compositions for modulating expression of sodium voltage-gated channel alpha subunit 2 and uses thereof |
| WO2025025493A1 (zh) * | 2023-08-03 | 2025-02-06 | 劲帆生物医药科技（武汉）有限公司 | 一种含有重叠开放阅读框的表达盒及应用 |
| CN117070518A (zh) * | 2023-08-03 | 2023-11-17 | 劲帆生物医药科技（武汉）有限公司 | 一种用于表达包含重叠开放阅读框的基因的表达盒及应用 |
| US12416019B2 (en) | 2023-08-03 | 2025-09-16 | Genevoyager (WUHAN) CO., LTD. | Expression cassette containing overlapping open reading frames and application |
| WO2025083591A2 (en) | 2023-10-17 | 2025-04-24 | Regel Therapeutics, Inc. | Genetic regulatory elements for cardiac tissue expression and uses thereof |
| WO2026017965A1 (en) | 2024-07-19 | 2026-01-22 | The University Court Of The University Of Edinburgh | Recombinant therapeutic fxn constructs and methods of treating friedreich ataxia and related conditions |
| WO2026043765A1 (en) | 2024-08-21 | 2026-02-26 | Eli Lilly And Company | Engineered regulatory splice elements for gene therapies |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| US6204059B1 (en) | 1994-06-30 | 2001-03-20 | University Of Pittsburgh | AAV capsid vehicles for molecular transfer |
| CA2207927A1 (en) | 1994-12-06 | 1996-06-13 | Targeted Genetics Corporation | Packaging cell lines for generation of high titers of recombinant aav vectors |
| US5688676A (en) | 1995-06-07 | 1997-11-18 | Research Foundation Of State University Of New York | In vitro packaging of adeno-associated virus DNA |
| US5741683A (en) | 1995-06-07 | 1998-04-21 | The Research Foundation Of State University Of New York | In vitro packaging of adeno-associated virus DNA |
| JP2001506133A (ja) | 1996-12-18 | 2001-05-15 | ターゲティッド ジェネティクス コーポレイション | 組換えａａｖベクターの産生における使用のための、ａａｖスプリット−パッケージング遺伝子およびこのような遺伝子を含む細胞株 |
| US6156303A (en) | 1997-06-11 | 2000-12-05 | University Of Washington | Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom |
| EP1124976A1 (de) | 1998-10-27 | 2001-08-22 | Crucell Holland B.V. | Verbesserte produktion von aav-vektoren |
| DE19905501B4 (de) | 1999-02-10 | 2005-05-19 | MediGene AG, Gesellschaft für molekularbiologische Kardiologie und Onkologie | Verfahren zur Herstellung eines rekombinanten Adeno-assoziierten Virus, geeignete Mittel hierzu sowie Verwendung zur Herstellung eines Arzneimittels |
| WO2003042361A2 (en) * | 2001-11-09 | 2003-05-22 | Government Of The United States Of America, Department Of Health And Human Services | Production of adeno-associated virus in insect cells |
| EP1588166A4 (de) * | 2003-01-09 | 2007-06-27 | Macrogenics Inc | Doppelexpressionsvektorsystem für die antikörperexpression in bakteriellen und säugetierzellen |
| CN1778812A (zh) * | 2004-11-24 | 2006-05-31 | 国家海洋环境监测中心 | 重组杆状病毒表达的诺瓦克样病毒衣壳蛋白及其制备方法 |
| WO2007084773A2 (en) | 2006-01-20 | 2007-07-26 | University Of North Carolina At Chapel Hill | Enhanced production of infectious parvovirus vectors in insect cells |
-
2007
- 2007-08-24 WO PCT/US2007/076799 patent/WO2008024998A2/en not_active Ceased
- 2007-08-24 EP EP07814439A patent/EP2061891B1/de active Active
- 2007-08-24 ES ES07814439T patent/ES2385679T3/es active Active
- 2007-08-24 US US12/297,958 patent/US8945918B2/en active Active
- 2007-08-24 AT AT07814439T patent/ATE553206T1/de active
- 2007-08-24 DK DK07814439.1T patent/DK2061891T3/da active
- 2007-08-24 CN CN2007800370312A patent/CN101522903B/zh active Active
-
2014
- 2014-06-05 US US14/297,165 patent/US20140329313A1/en not_active Abandoned
- 2014-10-03 US US14/505,847 patent/US9879279B2/en active Active
-
2016
- 2016-08-01 US US15/224,984 patent/US9879282B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2061891B1 (de) | 2012-04-11 |
| CN101522903B (zh) | 2013-07-31 |
| EP2061891A4 (de) | 2010-07-28 |
| WO2008024998A3 (en) | 2008-11-06 |
| US8945918B2 (en) | 2015-02-03 |
| EP2061891A2 (de) | 2009-05-27 |
| US20140329313A1 (en) | 2014-11-06 |
| US20090203071A1 (en) | 2009-08-13 |
| US9879282B2 (en) | 2018-01-30 |
| DK2061891T3 (da) | 2012-07-23 |
| WO2008024998A2 (en) | 2008-02-28 |
| ES2385679T3 (es) | 2012-07-30 |
| CN101522903A (zh) | 2009-09-02 |
| US20150031115A1 (en) | 2015-01-29 |
| US9879279B2 (en) | 2018-01-30 |
| US20160333375A1 (en) | 2016-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE553206T1 (de) | Expression von genen mit überlappenden offenen leserastern in insektenzellen, verfahren und zusammensetzungen dafür | |
| Zhu | Mammalian cell protein expression for biopharmaceutical production | |
| Zheng et al. | Metagenomic and metaproteomic insights into photoautotrophic and heterotrophic interactions in a Synechococcus culture | |
| EA201492202A1 (ru) | Способ экспрессии гетерологичных белков с использованием рекомбинантного вирусного вектора с минус-нитью рнк | |
| MX2007003906A (es) | Metodos y composiciones para mejorar la produccion de proteinas recombinantes. | |
| TR201806812T4 (tr) | Rna-yönlendirmeli hedef dna modifikasyonu için ve rna-yönlendirmeli transkripsiyon modifikasyonu için yöntemler ve bileşimler. | |
| WO2003102201A3 (en) | Methods and materials for the production of d-lactic acid in yeast | |
| EA201590167A1 (ru) | Способы и композиции для лечения генетического заболевания | |
| ATE512980T1 (de) | Polypeptide mit beta-glucosidase-aktivität sowie diese codierende polynukleotide | |
| DK1805296T3 (da) | Stabil genomisk integrering af multipie polynukleotidkopier | |
| EP2379577A4 (de) | Zusammensetzungen und verfahren zur umprogrammierung von zellen ohne genetische modifikation | |
| TN2014000069A1 (en) | Protein expression | |
| WO2014097113A3 (en) | Production of therapeutic proteins in genetically modified mammalian cells | |
| EP2330200A3 (de) | Genexpressionstechnik | |
| WO2011163531A3 (en) | Compositions and methods for re-programming cells without genetic modification for treatment of cardiovascular diseases | |
| ATE494381T1 (de) | Verbesserte expressionselemente | |
| JP2009534036A5 (de) | ||
| Alva et al. | Translational landscape and protein biogenesis demands of the early secretory pathway in Komagataella phaffii | |
| ATE524563T1 (de) | System zur herstellung synthetischer promotoren | |
| ATE532861T1 (de) | Expressionsvektor | |
| DE60135325D1 (de) | Bakteriocin gegen listeria | |
| JP2016519575A5 (de) | ||
| EP1930416A4 (de) | Neues rekombinantes partikel mit ähnlichkeit zum menschlichen hepatitis-c-virus und verfahren zur herstellung davon | |
| JP2005532815A5 (de) | ||
| NZ778367A (en) | Cell-specific transcriptional regulatory sequences and uses thereof |